50P - Prognostic value of disseminated tumor cells (DTC) identification in bone marrow from patients with advanced gastric or esophagogastric junction (E...

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Oesophageal Cancer
Gastric Cancer
Translational Research
Presenter Ekaterina Obarevich
Citation Annals of Oncology (2015) 26 (suppl_9): 8-15. 10.1093/annonc/mdv518
Authors E.S. Obarevich1, N.S. Besova2, N.N. Tupitsyn3, M.M. Davydov4, V.A. Gorbunova2, T.A. Titova2
  • 1Chemotherapy, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 2Chemotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 3Haematopoiesis Immunology Lab., N. N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 4Thoraco-abdominal, N. N. Blokhin Russian Cancer Research Center, Moscow/RU

Abstract

Aim/Background

To identify DTC in bone marrow (BM) as a therapeutically significant target to predict survival of patients with stage IV gastric cancer.

Methods

A total of 27 patients with advanced gastric cancer were enrolled, median age 52 years. All patients received thriplet chemotherapy. Baseline BM-DCT were identified by flow cytometry. BM-DTC positivity was defined as at least 1 tumor cell per 10 million myelokaryocytes.

Results

BM-DTC were found in 18 of 27 patients. Median survival was 6.5 months in BM-DTC positive vs. 9.2 months in BM-DTC negative patients (p = 0.019). The table below summarizes the clinicomorphological findings. Table. Relationship between DTC-positivity and clinicomorphological parameters.

Parameter BM-DTC positive patients n, % BM-DTC negative patients n, % p-Value
Tumor site
Esophagogastric junction 9/18 (50) 1/9 (11.1) 0.049
Body of stomach 6/18 (33.3) 4/9 (44.4) 0.573
Anthrum 3/18 (16.7) 2/9 (22.2) 0.726
Total stomach 0/18 (0) 2/9 (22.2) 0.038
Adenocarcinoma histology
Moderately differentiated 4/18 (22.2) 2/9 (22.2) 1
Poorly differentiated 10/18 (55.6) 1/9 (11.1) 0.027
Signet-ring cell 4/18 (22.2) 6/9 (66.7) 0.024
Metastasis sites
Liver 6/18 (33.3) 3/9 (33.3) 1
Peripheral lymph nodes 4/18 (22.2) 3/9 (33.3) 0.535
Retroperitoneal lymph nodes 8/18 (44.4) 2/9 (22.2) 0.260
Ovaries 1/18 (5.6) 1/9 (11.1) 0.603
Peritoneal carcinomatosis 9/18 (50) 8/9 (88.9) 0.049

Conclusions

The presence of DTC in BM of patients with advanced gastric cancer is a poor prognostic factor associated with a high risk of early progression. BM-DTC were identified significantly more frequently in cases with EGJ and total gastric cancer, and in patients free from peritoneal carcinomatosis; there was also a correlation with tumor histology. The study is in ongoing

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.